Sign inJoin waitlistJoin the waitlist

Ruqin Chen

Oncologist · Mayo Clinic College of Medicine and Science

Credentials: · · · · · · ·

History

Mayo Clinic College of Medicine and Science
Present

Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
2017–2020
Internal Medicine
2014–2017
Doctor of Medicine
1991–1995

Research

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer
Journal of Clinical Oncology · 2009 · 318 citations
Emerging therapeutic agents for advanced non-small cell lung cancer
Review · Journal of Hematology & Oncology · 2020 · First of 9 authors · 267 citations
The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers
Review · OncoTargets and Therapy · 2017 · 48 citations

CO
Coleman Obasaju
10 papers
Yujie Zhao
7 papers
JT
Joseph Treat
6 papers
Rami Manochakian
6 papers
Yanyan Lou
6 papers
MS
Mark Socinski
5 papers
Arkadiusz Dudek
4 papers
CB
Chandra Belani
3 papers
Martin Edelman
3 papers
RA
Rafat Ansari
3 papers
Robert McWilliams
3 papers
Roxana Dronca
3 papers

Clinical trials

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Principal investigator · Completed · Early phase 1
Mayo Clinic
2017–2019
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Site PI · Recruiting · Phase 2, Phase 3
TuHURA Biosciences, Inc.
2025–2032
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Site PI · Recruiting · Phase 1, Phase 2
Perspective Therapeutics
2023–2029
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Site PI · Recruiting · Phase 1
Pierre Fabre Medicament
2021–2029